You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 22, 2024

ALLEGRA HIVES Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


Which patents cover Allegra Hives, and when can generic versions of Allegra Hives launch?

Allegra Hives is a drug marketed by Chattem Sanofi and is included in one NDA.

The generic ingredient in ALLEGRA HIVES is fexofenadine hydrochloride. There are twenty-three drug master file entries for this compound. One hundred and four suppliers are listed for this compound. Additional details are available on the fexofenadine hydrochloride profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Allegra Hives

A generic version of ALLEGRA HIVES was approved as fexofenadine hydrochloride by TEVA on September 1st, 2005.

  Sign Up

AI Research Assistant
Questions you can ask:
  • What is the 5 year forecast for ALLEGRA HIVES?
  • What are the global sales for ALLEGRA HIVES?
  • What is Average Wholesale Price for ALLEGRA HIVES?
Drug patent expirations by year for ALLEGRA HIVES
Recent Clinical Trials for ALLEGRA HIVES

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Food and Drug Administration (FDA)Early Phase 1
University of California, San FranciscoEarly Phase 1
University of Alabama at BirminghamPhase 2

See all ALLEGRA HIVES clinical trials

Pharmacology for ALLEGRA HIVES

US Patents and Regulatory Information for ALLEGRA HIVES

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Chattem Sanofi ALLEGRA HIVES fexofenadine hydrochloride TABLET;ORAL 020872-008 Jan 24, 2011 DISCN Yes No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Chattem Sanofi ALLEGRA HIVES fexofenadine hydrochloride TABLET;ORAL 020872-009 Jan 24, 2011 OTC Yes Yes ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for ALLEGRA HIVES

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Chattem Sanofi ALLEGRA HIVES fexofenadine hydrochloride TABLET;ORAL 020872-009 Jan 24, 2011 ⤷  Sign Up ⤷  Sign Up
Chattem Sanofi ALLEGRA HIVES fexofenadine hydrochloride TABLET;ORAL 020872-009 Jan 24, 2011 ⤷  Sign Up ⤷  Sign Up
Chattem Sanofi ALLEGRA HIVES fexofenadine hydrochloride TABLET;ORAL 020872-009 Jan 24, 2011 ⤷  Sign Up ⤷  Sign Up
Chattem Sanofi ALLEGRA HIVES fexofenadine hydrochloride TABLET;ORAL 020872-008 Jan 24, 2011 ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

International Patents for ALLEGRA HIVES

See the table below for patents covering ALLEGRA HIVES around the world.

Country Patent Number Title Estimated Expiration
Canada 2254506 DERIVES DE LA PIPERIDINE ET METHODE DE PREPARATION (PIPERIDINE DERIVATIVES AND PROCESS FOR THEIR PRODUCTION) ⤷  Sign Up
Norway 944287 ⤷  Sign Up
European Patent Office 0766668 PROCEDES DE PREPARATION DE FORMES ANHYDRES ET HYDRATEES DE DERIVES DE PIPERIDINE ANTIHISTAMINIQUES, POLYMORPHES ET PSEUDOMORPHES DE CES DERNIERES (PROCESSES FOR PREPARING ANHYDROUS AND HYDRATE FORMS OF ANTIHISTAMINIC PIPERIDINE DERIVATIVES, POLYMORPHS AND PSEUDORMOPHS THEREOF) ⤷  Sign Up
Germany 69433346 ⤷  Sign Up
>Country >Patent Number >Title >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.